MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Futura Medical confirms Europe launch of MED3000; awaits FDA approval

ALN

Futura Medical PLC on Tuesday said its MED3000 product is now available online in Europe under the brand name Erexon.

The sexual health-focused pharmaceutical company, based in Surrey, England, said Erexon will also be available to buy in pharmacies in Belgium as of April.

This comes after Futura Medical announced a licensing agreement with Cooper Consumer Health last year for the rights to commercialise MED3000 in Europe, Switzerland and the UK.

MED3000 is a gel developed by Futura Medical used to treat erectile dysfunction.

The company also said it applied for US marketing authorisation for MED3000, which is undergoing a review. The US Food and Drug Administration has asked questions on MED3000, which Futura Medical plans to respond to at the end of the month.

Chief Executive Officer James Barder said the company expects to be granted market authorisation by the FDA in the second half of 2023.

If successful, MED3000 would become the first globally available, clinically proven, over the counter treatment for erectile dysfunction.

Shares were down 3.8% at 48.19 pence in London on Tuesday afternoon.

Copyright 2023 Alliance News Ltd. All Rights Reserved.